官方服务：
资源简介：
Dataset is on HIV vaccine clinical trials sponsored by the HNTN.
应用场景：
创建时间：
2021-01-21
相关数据集
Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: A randomized, controlled trial of DAR-901
Background Development of a tuberculosis vaccine to boost BCG is a major international health priority. SRL172, an inactivated whole cell booster derived from a non-tuberculous mycobacterium, is the o
NIAID Data Ecosystem30
Seropositivity/seroprotection rates and GMTs/GMCs before and 1 month after primary vaccination (ATP cohort for the primary immunogenicity study)
*DTPw-HBV/Hib-MenAC **DTPw-HBV/Hib PSC/A = serogroup S/A polysaccharide ; PRP = polyribosylribitol phosphate; BPT = Bortedella pertussis ; HBs = Hepatitis B surface antigen Dilution titre (SBA), μg/ml
NIAID Data Ecosystem20
Safety and Immunogenicity of an HIV-1 Gag DNA Vaccine with or without IL-12 and/or IL-15 Plasmid Cytokine Adjuvant in Healthy, HIV-1 Uninfected Adults
BackgroundDNA vaccines are a promising approach to vaccination since they circumvent the problem of vector-induced immunity. DNA plasmid cytokine adjuvants have been shown to augment immune responses
NIAID Data Ecosystem10
Additional file 1 of A retrospective analysis of incident pregnancy in phase 1 and 2a HIV-1 vaccine study participants does not support concern for adverse pregnancy or birth outcomes
Additional file 1: Fig. S1. Pregnancy outcomes in HVTN vaccine studies that occurred at any time following enrollment.
DataCite Commons2021-08-12 更新30
Dataset from An Observer-blind, Dose Ranging Safety and Immunogenicity Study of GSK Biologicals' GSK1557484A Vaccine in Children 6 to Less Than 36 Months of Age
The purpose of this study is to assess the safety and immunogenicity of different formulations of GSK Biologicals' influenza candidate vaccine GSK1557484A, in children 6-35 months of age.
NIAID Data Ecosystem20
